Background 

In 2022, as war escalated in Ukraine, businesses faced unprecedented challenges. Farmak, the nation’s largest pharmaceutical manufacturer, had to ensure the safety and security of its employees while maintaining critical operations. Amid six million Ukrainians fleeing abroad and near five million internally displaced Farmak’s mission was clear: protect and retain its employees, continue manufacturing life-saving medicines and provide stability despite the turmoil.

Operating in Kyiv and Shostka, both impacted by the war, the company also evacuated staff from conflict-heavy Kharkiv. To address these challenges Farmak launched a comprehensive wellbeing initiative, ensuring safety, security and stability for its workforce and support for those serving in Ukraine’s Armed Forces.

Approach 

Farmak’s initiative prioritised employee safety and stability in multiple ways. Before the conflict intensified the company had already begun constructing bomb shelters at plants, warehouses and offices. These shelters were specifically equipped to protect employees from missile strikes and chemical threats during air raids. Regular emergency drills ensured that staff knew how to act in a crisis. To avoid operational disruptions Farmak invested €1.2 million in generators, enabling 26 production units to continue through blackouts.

Beyond physical safety Farmak focused on financial and emotional wellbeing. The company raised wages three times, continued to pay salaries and bonuses and offered free health insurance – not mandated in Ukraine. Employees serving in the military received full salaries and essential equipment like drones and vehicles. For families of fallen employees Farmak ensured continued financial support until their children reached adulthood.

“Farmak has become an island of stability and security, supporting its employees and continuing to deliver life-saving medicines amid the war in Ukraine”

Flexible work arrangements, legal counselling, expanded health insurance and opportunities for development were also provided, the latter particularly important to demonstrate confidence in the future. The company, which currently has 83 employees at the frontline, also donated more than €4.7 million to support the Armed Forces of Ukraine and responded to humanitarian needs since the start of the full-scale war.

Outcome

Farmak’s efforts yielded impressive results. Employee turnover is just 7%, far below the Ukrainian market average of 12%. The company retained its entire 2,800-strong workforce, with an average tenure of nine years, reflecting loyalty and commitment. Despite the war production levels were maintained, 22 new products launched and medicines continued to be supplied both within Ukraine and internationally.

Recognised as a top employer Farmak was ranked as Ukraine’s leading pharmaceutical company by Forbes in 2023. Employees report feeling secure and supported, with the company’s investments fostering a resilient, purpose-driven workforce amid ongoing conflict.